$CCEL
CRYO CELL INTERNATIONAL INC

2019 Q2 Form 10-Q Financial Statement

#000119312519194098 Filed on July 15, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2018 Q4 2018 Q2
Revenue $8.128M $8.594M $6.525M
YoY Change 24.56% 32.82% 4.63%
Cost Of Revenue $2.628M $2.675M $1.777M
YoY Change 47.89% 63.1% 11.63%
Gross Profit $5.500M $5.919M $4.748M
YoY Change 15.82% 22.29% 2.23%
Gross Profit Margin 67.66% 68.87% 72.77%
Selling, General & Admin $3.648M $4.120M $3.533M
YoY Change 3.25% 16.37% 3.56%
% of Gross Profit 66.33% 69.6% 74.41%
Research & Development $4.957K $26.92K $29.28K
YoY Change -83.07% 34.6% 231.27%
% of Gross Profit 0.09% 0.45% 0.62%
Depreciation & Amortization $103.4K $103.1K $60.00K
YoY Change 72.38% 71.75% 20.0%
% of Gross Profit 1.88% 1.74% 1.26%
Operating Expenses $3.653M $4.202M $3.562M
YoY Change 2.54% 17.04% 4.14%
Operating Profit $496.6K $1.717M $1.150M
YoY Change -56.81% 37.36% -3.57%
Interest Expense $424.3K -$551.5K $304.1K
YoY Change 39.52% 49.04% -6.52%
% of Operating Profit 85.44% -32.12% 26.45%
Other Income/Expense, Net -$391.9K -$39.24K -$294.3K
YoY Change 33.18% 96.2% -19.05%
Pretax Income $104.6K $1.542M $855.4K
YoY Change -87.77% 79.26% 3.23%
Income Tax $50.94K $557.7K $315.9K
% Of Pretax Income 48.7% 36.18% 36.93%
Net Earnings $53.67K $890.8K $539.5K
YoY Change -90.05% 30.99% 8.57%
Net Earnings / Revenue 0.66% 10.37% 8.27%
Basic Earnings Per Share $0.01 $0.07
Diluted Earnings Per Share $0.01 $114.2K $0.07
COMMON SHARES
Basic Shares Outstanding 7.803M 7.801M shares 7.247M
Diluted Shares Outstanding 8.421M 7.918M

Balance Sheet

Concept 2019 Q2 2018 Q4 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.308M $6.916M $7.110M
YoY Change 2.79% 2.91% 37.26%
Cash & Equivalents $6.469M $6.040M $6.541M
Short-Term Investments $839.8K $875.7K $570.0K
Other Short-Term Assets $278.1K $254.5K $190.4K
YoY Change 46.07% 23.45% 22.53%
Inventory $1.046M $1.261M $424.5K
Prepaid Expenses $610.6K $461.8K $488.8K
Receivables $5.867M $5.867M $4.820M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $15.00M $14.76M $13.04M
YoY Change 15.07% 15.88% 22.04%
LONG-TERM ASSETS
Property, Plant & Equipment $1.748M $1.493M $1.038M
YoY Change 68.37% 69.25% 16.96%
Goodwill $1.941M $1.941M
YoY Change
Intangibles $1.288M $1.341M $404.1K
YoY Change 218.6% 492.42% 65.82%
Long-Term Investments $308.0K $308.0K
YoY Change
Other Assets $24.14M $26.14M $8.145M
YoY Change 196.37% 153.99% -13.96%
Total Long-Term Assets $25.89M $28.13M $9.183M
YoY Change 181.91% 151.73% -11.31%
TOTAL ASSETS
Total Short-Term Assets $15.00M $14.76M $13.04M
Total Long-Term Assets $25.89M $28.13M $9.183M
Total Assets $40.89M $42.89M $22.22M
YoY Change 84.02% 79.36% 5.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.029M $1.262M $1.113M
YoY Change -7.56% -34.58% -6.07%
Accrued Expenses $965.0K $2.703M $2.182M
YoY Change -55.78% 4.66% -17.21%
Deferred Revenue $8.365M $8.365M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.100M $3.100M $2.000M
YoY Change 55.0% 55.0% 0.0%
Total Short-Term Liabilities $13.61M $15.43M $12.80M
YoY Change 6.35% 10.69% -1.38%
LONG-TERM LIABILITIES
Long-Term Debt $1.425M $1.425M $1.425M
YoY Change 0.0% 0.0% 0.0%
Other Long-Term Liabilities $35.37M $35.87M $23.52M
YoY Change 50.38% 59.61% 5.27%
Total Long-Term Liabilities $36.80M $37.29M $24.95M
YoY Change 47.5% 56.05% 4.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.61M $15.43M $12.80M
Total Long-Term Liabilities $36.80M $37.29M $24.95M
Total Liabilities $48.98M $51.30M $36.32M
YoY Change 34.86% 40.88% 2.83%
SHAREHOLDERS EQUITY
Retained Earnings -$24.41M -$25.33M -$26.47M
YoY Change -7.78% 3.49% 2.55%
Common Stock $35.88M $35.65M $31.78M
YoY Change 12.93% 13.17% 2.54%
Preferred Stock
YoY Change
Treasury Stock (at cost) $19.57M $19.57M $19.57M
YoY Change 0.0% 0.0% 0.22%
Treasury Stock Shares $5.801M $5.801M 5.801M shares
Shareholders Equity -$8.094M -$8.908M -$14.10M
YoY Change
Total Liabilities & Shareholders Equity $40.89M $42.39M $22.22M
YoY Change 84.02% 77.29% 5.63%

Cashflow Statement

Concept 2019 Q2 2018 Q4 2018 Q2
OPERATING ACTIVITIES
Net Income $53.67K $890.8K $539.5K
YoY Change -90.05% 30.99% 8.57%
Depreciation, Depletion And Amortization $103.4K $103.1K $60.00K
YoY Change 72.38% 71.75% 20.0%
Cash From Operating Activities $527.7K $844.0K $30.00K
YoY Change 1658.93% -60.0% -98.46%
INVESTING ACTIVITIES
Capital Expenditures -$359.8K -$37.86K $0.00
YoY Change -5.35%
Acquisitions
YoY Change
Other Investing Activities -$31.06K $20.00K
YoY Change -203.53% -33.33%
Cash From Investing Activities -$359.8K -$68.93K $10.00K
YoY Change -3697.8% 244.65% -75.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -775.0K -1.775M -500.0K
YoY Change 55.0% 269.79% -36.71%
NET CHANGE
Cash From Operating Activities 527.7K 844.0K 30.00K
Cash From Investing Activities -359.8K -68.93K 10.00K
Cash From Financing Activities -775.0K -1.775M -500.0K
Net Change In Cash -607.1K -999.9K -460.0K
YoY Change 31.98% -162.11% -138.33%
FREE CASH FLOW
Cash From Operating Activities $527.7K $844.0K $30.00K
Capital Expenditures -$359.8K -$37.86K $0.00
Free Cash Flow $887.5K $881.8K $30.00K
YoY Change 2858.2% -58.98% -98.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1747762
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1493401
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6468587
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6040033
CY2019Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
839809
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
875689
CY2019Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
610581
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
461815
CY2019Q2 us-gaap Inventory Net
InventoryNet
1046195
CY2018Q4 us-gaap Inventory Net
InventoryNet
1260557
CY2019Q2 us-gaap Other Assets Current
OtherAssetsCurrent
278143
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
254465
CY2019Q2 us-gaap Assets Current
AssetsCurrent
15001988
CY2018Q4 us-gaap Assets Current
AssetsCurrent
14759894
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1028999
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1261653
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
965009
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2702788
CY2019Q2 us-gaap Liabilities
Liabilities
48983177
CY2018Q4 us-gaap Liabilities
Liabilities
51298441
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
40889385
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42390143
CY2019Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1287545
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1341336
CY2019Q2 us-gaap Goodwill
Goodwill
1941411
CY2018Q4 us-gaap Goodwill
Goodwill
1941411
CY2019Q2 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
7562705
CY2018Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
7656897
CY2019Q2 ccel Deposits And Other Assets
DepositsAndOtherAssets
393974
CY2018Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
113888
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
24139635
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
26136848
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
13610601
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15429725
CY2019Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
3612048
CY2018Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
4282975
CY2019Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1425000
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1425000
CY2019Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
35372576
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
35868716
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
135989
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
135964
CY2019Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
35746866
us-gaap Costs And Expenses
CostsAndExpenses
14272738
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
us-gaap Costs And Expenses
CostsAndExpenses
10616708
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
32339
CY2018Q2 us-gaap Costs And Expenses
CostsAndExpenses
5375727
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
35515382
CY2019Q2 us-gaap Treasury Stock Value
TreasuryStockValue
19571113
CY2018Q4 us-gaap Treasury Stock Value
TreasuryStockValue
19571113
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
340984
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24405534
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25329515
CY2019Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2432645
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2264848
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13598909
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7803333
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13596409
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7800833
CY2019Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2628291
CY2018Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1777138
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5094518
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3378646
CY2019Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3647927
CY2018Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3533057
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7393229
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7122576
CY2019Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1037984
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4957
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29284
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10841
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42693
CY2019Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
55334
CY2018Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
36248
us-gaap Depreciation And Amortization
DepreciationAndAmortization
112314
us-gaap Depreciation And Amortization
DepreciationAndAmortization
72793
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
7631288
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9785
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-33854
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-23780
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-391948
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-294309
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-865066
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-608851
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
104616
CY2018Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
855427
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-995080
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
385362
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
185107
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
329550
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1870566
us-gaap Profit Loss
ProfitLoss
329550
us-gaap Profit Loss
ProfitLoss
-1990566
us-gaap Adjustment For Amortization
AdjustmentForAmortization
208300
us-gaap Adjustment For Amortization
AdjustmentForAmortization
120338
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-670927
us-gaap Share Based Compensation
ShareBasedCompensation
225809
us-gaap Share Based Compensation
ShareBasedCompensation
268386
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1544298
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
485160
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1528022
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
53673
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
540760
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
3023437
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
57999
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
51540
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
276700
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-120671
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
148766
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
116666
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-10915
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
109928
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
23678
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-15720
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
-49145
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
700000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-232654
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-815400
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1719371
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-400376
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1818095
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2071632
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2345842
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1723895
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
408870
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
253704
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
200000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-35880
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
13283
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-372990
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-466987
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1549998
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1000000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5700
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4920
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
428554
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
261828
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6279154
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6540982
CY2019Q2 us-gaap Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
-340984
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-8908298
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-12502896
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5700
CY2019Q2 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
22000
CY2018Q2 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
22000
us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
22000
us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
22000
ccel Minimum Percentage Probability Of Realized Tax Benefit On Settlement
MinimumPercentageProbabilityOfRealizedTaxBenefitOnSettlement
0.50
CY2019Q2 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
87000
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
156000
CY2018Q2 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
7610357
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
14293369
CY2018Q2 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-569088
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
225809
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4920
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
268386
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
120000
CY2019Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8127852
CY2018Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6525463
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15622964
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
12753581
CY2019Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
365086
CY2018Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
329231
CY2019Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5758673
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5867335
CY2019Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8516593
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8365284
CY2019Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
21984017
CY2018Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
20317231
CY2019Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
30500610
CY2019Q2 ccel Revenue Remaining Performance Obligation Next Twelve Months
RevenueRemainingPerformanceObligationNextTwelveMonths
8516593
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2012Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
75000
CY2017Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
100000
CY2017Q2 ccel Reimbursement Of Personal Expenses
ReimbursementOfPersonalExpenses
10000
CY2019Q2 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
7826
us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
14469
CY2018Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
329231
CY2018Q4 us-gaap Capitalized Contract Cost Accumulated Amortization
CapitalizedContractCostAccumulatedAmortization
66533
CY2019Q2 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
20954
ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
23534
CY2019Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1634000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1634000
CY2019Q2 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
29000
CY2018Q2 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
294000
us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
134000
us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
3497000
ccel Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
2985000
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
226000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
268000
CY2018Q2 us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
9016
us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
-25208
CY2019Q1 ccel Cumulative Effect Adjustment From Accumulated Other Comprehensive Income To Retained Earnings
CumulativeEffectAdjustmentFromAccumulatedOtherComprehensiveIncomeToRetainedEarnings
341000
CY2019Q2 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
31000
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
CY2017Q2 ccel Increased Payment Warranty
IncreasedPaymentWarranty
100000
CY2012Q1 ccel Additional Payment Warranty
AdditionalPaymentWarranty
10000
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-4049426
CY2018Q2 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-0.07
CY2018Q2 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-0.07
us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-0.53
us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-0.53
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7803333
us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 18pt;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Product Warranty and Cryo-Cell Cares</div><div style="vertical-align: super;font-size: smaller;display:inline;"><div style="font-weight:bold;display:inline;">TM</div></div><div style="font-weight:bold;display:inline;"> Program </div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 6pt; text-indent: 0.79in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February&#160;1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients. Effective June&#160;1, 2017, the Company increased the payment warranty to $100,000 to all new clients who choose the premium processing method, Prepacyte CB. Additionally, under the Cryo-Cell CaresTM program, the Company will pay $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloblative transplant procedure. The product warranty and the Cryo-Cell Cares program are available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties.</div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 1pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 6pt; text-indent: 0.79in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As discussed above, the Company has determined that the payment warranty represents variable consideration payable to the customer. Upon the adoption of ASC 606, the Company has concluded the payment warranty be fully constrained under the most likely amount method, therefore, the transaction price does not reflect any expectation of service level credits at May&#160;31, 2019.&#160;&#160;&#160;&#160;At the end of each reporting period, the Company shall update the estimated transaction price related to the payment guarantee including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q2 ccel Allocated Share Based Compensation Expenses Reversed
AllocatedShareBasedCompensationExpensesReversed
444000
ccel Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Shares Settled For Cash In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesSettledForCashInPeriod
30000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
496564
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
1149736
CY2019Q2 us-gaap Interest Expense
InterestExpense
424287
CY2018Q2 us-gaap Interest Expense
InterestExpense
304094
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
50943
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
315921
us-gaap Operating Income Loss
OperatingIncomeLoss
1350226
us-gaap Operating Income Loss
OperatingIncomeLoss
2136873
us-gaap Interest Expense
InterestExpense
831212
us-gaap Interest Expense
InterestExpense
585071
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
155610
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3518588
CY2019Q2 us-gaap Assets
Assets
40889385
CY2018Q4 us-gaap Assets
Assets
42390143
CY2019Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
0
CY2019Q2 ccel Inventory Collection Kits
InventoryCollectionKits
21021
CY2018Q4 ccel Inventory Collection Kits
InventoryCollectionKits
19163
CY2019Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2018Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2019Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1287545
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1341336
CY2019Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
27000
CY2018Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
54000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
22000
CY2019Q2 us-gaap Notes Payable
NotesPayable
11658433
CY2018Q4 us-gaap Notes Payable
NotesPayable
13208433
CY2019Q2 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
206922
CY2018Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
264923
CY2019Q2 us-gaap Long Term Debt
LongTermDebt
11451511
CY2018Q4 us-gaap Long Term Debt
LongTermDebt
12943510
CY2019Q2 us-gaap Notes Payable Current
NotesPayableCurrent
3100000
CY2018Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3100000
CY2019Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
8351511
CY2018Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9843510
CY2019Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
181440
us-gaap Interest Expense Debt
InterestExpenseDebt
361682
CY2019Q2 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
28106
ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
58000
CY2019Q2 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
209546
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
419682
CY2018Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
94818
us-gaap Interest Expense Debt
InterestExpenseDebt
188645
CY2018Q2 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
24837
ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
51540
CY2018Q2 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
119655
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
240185
CY2019Q2 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
548085
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
53673
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
539506
us-gaap Net Income Loss
NetIncomeLoss
329550
us-gaap Net Income Loss
NetIncomeLoss
-1990566
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7803333
CY2018Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7247464
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7802344
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7177082
CY2019Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
617903
CY2018Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
670271
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
619798
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8421236
CY2018Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7917735
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8422142
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7177082
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
40254
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.04
CY2019Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
49000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Description And Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms
The options were issued under the Company's 2012 Stock Plan and will vest 1/3 upon grant, 1/3 on December 1, 2018 and the remaining 1/3 on November 30, 2019
CY2019Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
39000
CY2018Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
91000
us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
25208
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-36000
dei Trading Symbol
TradingSymbol
CCEL
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2019Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
992865
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P3Y6M25D
CY2019Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
2.79
CY2019Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
969821
CY2019Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
2.69
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1500
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.28
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
18710
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
3.23
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
0
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
23044
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
2.94
ccel Description On Second Amendment To Employment Agreement
DescriptionOnSecondAmendmentToEmploymentAgreement
The Amendment provides for the grant of shares of the Company&#8217;s common stock based on certain performance measures being attained by the Company during fiscal year 2016 and fiscal year 2017. The Amendment states if Executive is employed by the Company on November 30, 2016 and November 30, 2017, then no later than February 28, 2017 and February 28, 2018, respectively, the Company will grant Executive up to 20,000 shares of restricted stock based on performance as set forth in the Amendment per each fiscal year.
us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
Open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
CY2019Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
5801086
CY2018Q2 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019Q2 ccel Number Of Employee Stock Based Compensation Plan
NumberOfEmployeeStockBasedCompensationPlan
2
CY2019Q2 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-8234292
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2019-05-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
CRYO CELL INTERNATIONAL INC
dei Entity Central Index Key
EntityCentralIndexKey
0000862692
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
0
CY2017 ccel Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cash Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCashPayments
444000
CY2011Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000
CY2012Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
6000000
CY2016Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
8000000
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
86827
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-8093792
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-14356377
CY2018Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2670
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
-287209
CY2018Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1254
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
-14100156
ccel Types Of License Agreements
TypesOfLicenseAgreements
2
CY2019Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
12646000
CY2018Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
14775316
CY2019Q2 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
2332763
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
2332763
CY2019Q2 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
13692195
CY2018Q4 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
16035873
dei Document Type
DocumentType
10-Q
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Shell Company
EntityShellCompany
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Address State Or Province
EntityAddressStateOrProvince
DE
dei Security Exchange Name
SecurityExchangeName
NONE
dei Security12b Title
Security12bTitle
Common Stock

Files In Submission

Name View Source Status
0001193125-19-194098-index-headers.html Edgar Link pending
0001193125-19-194098-index.html Edgar Link pending
0001193125-19-194098.txt Edgar Link pending
0001193125-19-194098-xbrl.zip Edgar Link pending
ccel-20190531.xml Edgar Link completed
ccel-20190531.xsd Edgar Link pending
ccel-20190531_cal.xml Edgar Link unprocessable
ccel-20190531_def.xml Edgar Link unprocessable
ccel-20190531_lab.xml Edgar Link unprocessable
ccel-20190531_pre.xml Edgar Link unprocessable
d751528d10q.htm Edgar Link pending
d751528dex311.htm Edgar Link pending
d751528dex312.htm Edgar Link pending
d751528dex313.htm Edgar Link pending
d751528dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending